

Nurcan Aşeyler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/944511/publications.pdf>

Version: 2024-02-01

161
papers

9,167
citations

44069

48
h-index

46799

89
g-index

188
all docs

188
docs citations

188
times ranked

8379
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of Religiosity for Coping Strategies and Disability in Patients with Fibromyalgia Syndrome. <i>Journal of Religion and Health</i> , 2022, 61, 524-539.	1.7	4
2	Treatment of Fabry Disease management with migalastatâ€™ outcome from a prospective 24 months observational multicenter study (FAMOUS). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 272-281.	3.0	33
3	Risk factors for depression and anxiety in painful and painless diabetic polyneuropathy: A multicentre observational crossâ€™sectional study. <i>European Journal of Pain</i> , 2022, 26, 370-389.	2.8	9
4	Profile of the singleâ€™use, multipleâ€™pass protein A adsorber column in immunoabsorption. <i>Vox Sanguinis</i> , 2022, 117, 393-398.	1.5	3
5	Unbiased immune profiling reveals a natural killer cell-peripheral nerve axis in fibromyalgia. <i>Pain</i> , 2022, 163, e821-e836.	4.2	16
6	A translational study: Involvement of miR-21-5p in development and maintenance of neuropathic pain via immune-related targets CCL5 and YWHAE. <i>Experimental Neurology</i> , 2022, 347, 113915.	4.1	6
7	Subepidermal <scp>Schwann</scp> cell counts correlate with skin innervation â€™ an exploratory study. <i>Muscle and Nerve</i> , 2022, 65, 471-479.	2.2	5
8	Gene variants of unknown significance in Fabry disease: Clinical characteristics of <i>c.376A>G (p.Ser126Gly)</i>. <i>Molecular Genetics & Genomic Medicine</i> , 2022, 10, e1912.	1.2	5
9	Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia Syndrome. <i>Cells</i> , 2022, 11, 1276.	4.1	8
10	Generation of the induced pluripotent stem cell line UKWNLi005-A derived from a patient with the GLA mutation c.376A>G of unknown pathogenicity in Fabry disease. <i>Stem Cell Research</i> , 2022, 61, 102747.	0.7	1
11	Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. <i>Molecular Genetics and Metabolism Reports</i> , 2022, 31, 100862.	1.1	4
12	CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement. <i>Scientific Reports</i> , 2022, 12, 6707.	3.3	9
13	Dorsal Root Ganglion Volumetry by MR Gangliography. <i>American Journal of Neuroradiology</i> , 2022, , .	2.4	2
14	Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease. <i>Cells</i> , 2022, 11, 1730.	4.1	6
15	Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge. <i>Pain Reports</i> , 2021, 6, e893.	2.7	36
16	The pathobiology of peripheral nerve disease: New clues from cell and molecular biology. <i>Neuroscience Letters</i> , 2021, 746, 135673.	2.1	0
17	Fibromyalgia vs small fiber neuropathy. <i>Pain</i> , 2021, Publish Ahead of Print, 2569-2577.	4.2	9
18	Complex regional pain syndrome: role of contralateral sensitisation. <i>British Journal of Anaesthesia</i> , 2021, 127, e1-e3.	3.4	11

#	ARTICLE	IF	CITATIONS
19	Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110043.	3.5	31
20	Differential impact of keratinocytes and fibroblasts on nociceptor degeneration and sensitization in small fiber neuropathy. <i>Pain</i> , 2021, 162, 1262-1272.	4.2	19
21	Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. <i>The Cochrane Library</i> , 2020, 2020, CD010292.	2.8	58
22	Pain-associated Mediators and Axon Pathfinders in Fibromyalgia Skin Cells. <i>Journal of Rheumatology</i> , 2020, 47, 140-148.	2.0	16
23	Pain-related evoked potentials in patients with large, mixed, and small fiber neuropathy. <i>Clinical Neurophysiology</i> , 2020, 131, 635-641.	1.5	11
24	Reduced association between dendritic cells and corneal subbasal nerve fibers in patients with fibromyalgia syndrome. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 9-18.	3.1	24
25	Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. <i>Experimental Neurology</i> , 2020, 324, 113134.	4.1	15
26	Idiopathic distal sensory polyneuropathy. <i>Neurology</i> , 2020, 95, 1005-1014.	1.1	49
27	Mechanisms of small nerve fiber pathology. <i>Neuroscience Letters</i> , 2020, 737, 135316.	2.1	6
28	English version of the self-administered Fabry Pain Questionnaire for adult patients. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 296.	2.7	2
29	MiR103a-3p and miR107 are related to adaptive coping in a cluster of fibromyalgia patients. <i>PLoS ONE</i> , 2020, 15, e0239286.	2.5	7
30	Cortical Binding Potential of Opioid Receptors in Patients With Fibromyalgia Syndrome and Reduced Systemic Interleukin-4 Levels – A Pilot Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 512.	2.8	6
31	Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 326-337.	4.7	41
32	Stratification of Fabry mutations in clinical practice: a closer look at Î-galactosidase A structure. <i>Journal of Internal Medicine</i> , 2020, 288, 593-604.	6.0	8
33	Characterization of dermal skin innervation in fibromyalgia syndrome. <i>PLoS ONE</i> , 2020, 15, e0227674.	2.5	13
34	Non-coding RNA regulators of diabetic polyneuropathy. <i>Neuroscience Letters</i> , 2020, 731, 135058.	2.1	9
35	ALS or ALS mimic by neuroborreliosis – A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 86-91.	0.5	2
36	Clustering fibromyalgia patients: A combination of psychosocial and somatic factors leads to resilient coping in a subgroup of fibromyalgia patients. <i>PLoS ONE</i> , 2020, 15, e0243806.	2.5	9

#	ARTICLE	IF	CITATIONS
37	A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 933-940.	3.4	128
38	Reduced gene expression of netrin family members in skin and sural nerve specimens of patients with painful peripheral neuropathies. <i>Journal of Neurology</i> , 2019, 266, 2812-2820.	3.6	8
39	Reduction of skin innervation is associated with a severe fibromyalgia phenotype. <i>Annals of Neurology</i> , 2019, 86, 504-516.	5.3	102
40	Patient-derived in vitro skin models for investigation of small fiber pathology. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1797-1806.	3.7	18
41	Tumor necrosis factor- β links heat and inflammation with Fabry pain. <i>Molecular Genetics and Metabolism</i> , 2019, 127, 200-206.	1.1	15
42	Small Fiber Pathology in Pain Syndromes. , 2019, , 121-129.		1
43	Affective and cognitive behavior is not altered by chronic constriction injury in B7-H1 deficient and wildtype mice. <i>BMC Neuroscience</i> , 2019, 20, 16.	1.9	8
44	Dyshidrosis is associated with reduced amplitudes in electrically evoked pain-related potentials in women with Fabry disease. <i>Clinical Neurophysiology</i> , 2019, 130, 528-536.	1.5	9
45	Generation of two induced pluripotent stem cell lines from skin fibroblasts of sisters carrying a c.1094C>A variation in the SCN10A gene potentially associated with small fiber neuropathy. <i>Stem Cell Research</i> , 2019, 35, 101396.	0.7	3
46	Neurophysiologische Diagnostik bei neuropathischen Schmerzen. <i>Neurophysiologie-Labor</i> , 2019, 41, 172-179.	0.0	0
47	Can self-reported pain characteristics and bedside test be used for the assessment of pain mechanisms? An analysis of results of neuropathic pain questionnaires and quantitative sensory testing. <i>Pain</i> , 2019, 160, 2093-2104.	4.2	27
48	Sensory profiles and immune-related expression patterns of patients with and without neuropathic pain after peripheral nerve lesion. <i>Pain</i> , 2019, 160, 2316-2327.	4.2	34
49	Increased pro-inflammatory cytokine gene expression in peripheral blood mononuclear cells of patients with polyneuropathies. <i>Journal of Neurology</i> , 2018, 265, 618-627.	3.6	34
50	Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1362-1372.	0.7	24
51	OCD-like behavior is caused by dysfunction of thalamo-amygdala circuits and upregulated TrkB/ERK-MAPK signaling as a result of SPRED2 deficiency. <i>Molecular Psychiatry</i> , 2018, 23, 444-458.	7.9	66
52	Inflammation in the pathophysiology of neuropathic pain. <i>Pain</i> , 2018, 159, 595-602.	4.2	318
53	Preserved Expression of Skin Neurotrophic Factors in Advanced Diabetic Neuropathy Does Not Lead to Neural Regeneration despite Pancreas and Kidney Transplantation. <i>Journal of Diabetes Research</i> , 2018, 1-11.	2.3	5
54	Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5. <i>Stem Cell Research</i> , 2018, 33, 171-174.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. <i>Human Molecular Genetics</i> , 2018, 27, 3392-3403.	2.9	34
56	Capsaicin 8% patch reversibly reduces A-delta fiber evoked potential amplitudes. <i>Pain Reports</i> , 2018, 3, e644.	2.7	10
57	Quantification of sweat gland innervation in patients with Fabry disease: A case-control study. <i>Journal of the Neurological Sciences</i> , 2018, 390, 135-138.	0.6	9
58	Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease. <i>Journal of Internal Medicine</i> , 2018, 284, 427-438.	6.0	13
59	Generation of the human induced pluripotent stem cell line (UKWNLi001-A) from skin fibroblasts of a woman with Fabry disease carrying the X-chromosomal heterozygous c.708â€C>â€C (W236C) missense mutation in exon 5 of the alpha-galactosidaseâ€A gene. <i>Stem Cell Research</i> , 2018, 31, 222-226.	0.7	6
60	Sensory profiles and skin innervation of patients with painful and painless neuropathies. <i>Pain</i> , 2018, 159, 1867-1876.	4.2	46
61	Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T. <i>Medicine (United States)</i> , 2018, 97, e10669.	1.0	4
62	Characterization of small fiber pathology in a mouse model of Fabry disease. <i>ELife</i> , 2018, 7, .	6.0	38
63	There is no functional smallâ€fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. <i>Experimental Dermatology</i> , 2017, 26, 969-971.	2.9	34
64	Anticonvulsants for fibromyalgia. <i>The Cochrane Library</i> , 2017, 2017, CD010782.	2.8	32
65	Î±-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	27
66	Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. <i>Pain</i> , 2017, 158, 2340-2353.	4.2	116
67	Aberrant microRNA expression in patients with painful peripheral neuropathies. <i>Journal of the Neurological Sciences</i> , 2017, 380, 242-249.	0.6	44
68	Reply. <i>Pain</i> , 2017, 158, 989-990.	4.2	2
69	ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. <i>Journal of Neurology</i> , 2017, 264, 11-20.	3.6	15
70	Cellular infiltrates in skin and sural nerve of patients with polyneuropathies. <i>Muscle and Nerve</i> , 2017, 55, 884-893.	2.2	17
71	Differential Impact of miR-21 on Pain and Associated Affective and Cognitive Behavior after Spared Nerve Injury in B7-H1 ko Mouse. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 219.	2.9	19
72	Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease. <i>PLoS ONE</i> , 2017, 12, e0180601.	2.5	17

#	ARTICLE	IF	CITATIONS
73	High-Resolution Ultrasonography of the Superficial Peroneal Motor and Sural Sensory Nerves May Be a Non-invasive Approach to the Diagnosis of Vasculitic Neuropathy. <i>Frontiers in Neurology</i> , 2016, 7, 48.	2.4	26
74	Endoneurial edema in sural nerve may indicate recent onset inflammatory neuropathy. <i>Muscle and Nerve</i> , 2016, 53, 705-710.	2.2	20
75	Severe Epidermal Nerve Fiber Loss in Diabetic Neuropathy Is Not Reversed by Long-Term Normoglycemia After Simultaneous Pancreas and Kidney Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 2196-2201.	4.7	22
76	Antipsychotics for fibromyalgia in adults. <i>The Cochrane Library</i> , 2016, 2016, CD011804.	2.8	25
77	Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 555-565.	10.2	176
78	Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 568-576.	3.9	75
79	Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. <i>BMJ Open</i> , 2016, 6, e010422.	1.9	45
80	Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 88.	2.7	29
81	Increased cutaneous miR-let-7d expression correlates with small nerve fiber pathology in patients with fibromyalgia syndrome. <i>Pain</i> , 2016, 157, 2493-2503.	4.2	58
82	Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development. <i>Molecular Pain</i> , 2016, 12, 174480691664637.	2.1	19
83	Increased miR-132-3p expression is associated with chronic neuropathic pain. <i>Experimental Neurology</i> , 2016, 283, 276-286.	4.1	93
84	Small fiber pathology—a culprit for many painful disorders?. <i>Pain</i> , 2016, 157, S60-S66.	4.2	29
85	Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch—2-Year Follow-Up. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 952-962.	6.1	38
86	Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease. <i>PLoS ONE</i> , 2016, 11, e0166484.	2.5	11
87	Expectation-Driven Text Extraction from Medical Ultrasound Images. <i>Studies in Health Technology and Informatics</i> , 2016, 228, 712-6.	0.3	0
88	Self-administered version of the Fabry-associated pain questionnaire for adult patients. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 113.	2.7	14
89	Increased cortical activation upon painful stimulation in fibromyalgia syndrome. <i>BMC Neurology</i> , 2015, 15, 210.	1.8	59
90	Clinical, histological, and biochemical predictors of postsurgical neuropathic pain. <i>Pain</i> , 2015, 156, 2390-2398.	4.2	32

#	ARTICLE	IF	CITATIONS
91	Amplitudes of Pain-Related Evoked Potentials Are Useful to Detect Small Fiber Involvement in Painful Mixed Fiber Neuropathies in Addition to Quantitative Sensory Testing – An Electrophysiological Study. <i>Frontiers in Neurology</i> , 2015, 6, 244.	2.4	21
92	The cardiomyopathy in Friedreich's ataxia – New biomarker for staging cardiac involvement. <i>International Journal of Cardiology</i> , 2015, 194, 50-57.	1.7	42
93	Increased gene expression of growth associated protein-43 in skin of patients with early-stage peripheral neuropathies. <i>Journal of the Neurological Sciences</i> , 2015, 355, 131-137.	0.6	18
94	Enhanced spinal neuronal responses as a mechanism for the increased nociceptive sensitivity of interleukin-4 deficient mice. <i>Experimental Neurology</i> , 2015, 271, 198-204.	4.1	14
95	Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. <i>Journal of Neurology</i> , 2015, 262, 2092-2100.	3.6	38
96	Differential gene expression of cytokines and neurotrophic factors in nerve and skin of patients with peripheral neuropathies. <i>Journal of Neurology</i> , 2015, 262, 203-212.	3.6	46
97	Pain: from new perspectives to novel treatments. <i>Lancet Neurology</i> , The, 2015, 14, 22-23.	10.2	3
98	Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease. <i>PLoS ONE</i> , 2014, 9, e87054.	2.5	30
99	Local and Systemic Cytokine Expression in Patients with Postherpetic Neuralgia. <i>PLoS ONE</i> , 2014, 9, e105269.	2.5	15
100	Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls. <i>BMC Neurology</i> , 2014, 14, 185.	1.8	14
101	Characterization of Pain in Fabry Disease. <i>Clinical Journal of Pain</i> , 2014, 30, 915-920.	1.9	83
102	Cutaneous activation of rage in nonsystemic vasculitic and diabetic neuropathy. <i>Muscle and Nerve</i> , 2014, 50, 377-383.	2.2	16
103	A comprehensive Fabry-related pain questionnaire for adult patients. <i>Pain</i> , 2014, 155, 2301-2305.	4.2	21
104	Neuropathic pain in two-generation twins carrying the sodium channel Nav1.7 functional variant R1150W. <i>Pain</i> , 2014, 155, 2199-2203.	4.2	12
105	High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know. <i>Pain and Therapy</i> , 2014, 3, 73-84.	3.2	39
106	Methylprednisolone prevents nerve injury-induced hyperalgesia in neprilysin knockout mice. <i>Pain</i> , 2014, 155, 574-580.	4.2	10
107	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. <i>Acta Neuropathologica</i> , 2014, 128, 99-109.	7.7	203
108	A Capsaicin (8%) Patch in the Treatment of Severe Persistent Inguinal Postherniorrhaphy Pain: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e109144.	2.5	37

#	ARTICLE	IF	CITATIONS
109	Local cytokine changes in complex regional pain syndrome type I (CRPS I) resolve after 6 months. Pain, 2013, 154, 2142-2149.	4.2	94
110	Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain, 2013, 154, 2569.	4.2	29
111	Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. The Cochrane Library, 2013, , CD010292.	2.8	96
112	Anticonvulsants for fibromyalgia. , 2013, , CD010782.		54
113	Small fibre pathology in patients with fibromyalgia syndrome. Brain, 2013, 136, 1857-1867.	7.6	400
114	Reply: Small fibre neuropathy, fibromyalgia and dorsal root ganglia sodium channels. Brain, 2013, 136, e247-e247.	7.6	5
115	Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study. BMC Neurology, 2013, 13, 47.	1.8	68
116	microRNAs in nociceptive circuits as predictors of future clinical applications. Frontiers in Molecular Neuroscience, 2013, 6, 33.	2.9	70
117	Lidocaine Patch (5%) in Treatment of Persistent Inguinal Postherniorrhaphy Pain. Anesthesiology, 2013, 119, 1444-1452.	2.5	45
118	CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 2012, 78, 402-408.	1.1	79
119	Cytokine-related and histological biomarkers for neuropathic pain assessment. Pain Management, 2012, 2, 391-398.	1.5	9
120	Sodium Channel Na _v 1.7 Is Essential for Lowering Heat Pain Threshold after Burn Injury. Journal of Neuroscience, 2012, 32, 10819-10832.	3.6	88
121	Cerebral Blood Flow in Patients With Fabry Disease as Measured by Doppler Sonography Is Not Different From That in Healthy Individuals and Is Unaffected by Treatment. Journal of Ultrasound in Medicine, 2012, 31, 463-468.	1.7	8
122	The Role of Antidepressants in the Management of Fibromyalgia Syndrome. CNS Drugs, 2012, 26, 297-307.	5.9	140
123	Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders, 2011, 12, 245.	1.9	204
124	Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neuroscience Letters, 2011, 495, 93-97.	2.1	31
125	IL-4 Deficiency Is Associated with Mechanical Hypersensitivity in Mice. PLoS ONE, 2011, 6, e28205.	2.5	59
126	Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. Journal of the Peripheral Nervous System, 2011, 16, 304-314.	3.1	82

#	ARTICLE	IF	CITATIONS
127	TNF-alpha in CRPS and "normal" trauma " Significant differences between tissue and serum. Pain, 2011, 152, 285-290.	4.2	82
128	Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment. Acta Neuropathologica, 2011, 122, 343-352.	7.7	20
129	Genetic Evidence for an Essential Role of Neuronally Expressed IL-6 Signal Transducer gp130 in the Induction and Maintenance of Experimentally Induced Mechanical Hypersensitivity <i>in vivo</i> and <i>in vitro</i> . Molecular Pain, 2011, 7, 1744-8069-7-73.	2.1	37
130	Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta-analysis. Arthritis Care and Research, 2011, 63, 808-820.	3.4	181
131	Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology, 2011, 50, 532-543.	1.9	264
132	Transient Receptor Potential Channel Polymorphisms Are Associated with the Somatosensory Function in Neuropathic Pain Patients. PLoS ONE, 2011, 6, e17387.	2.5	123
133	Neuropathic Pain Assessment - An Overview of Existing Guidelines and Discussion Points for the Future. European Neurological Review, 2011, 6, 128.	0.5	8
134	Skin biopsy as an additional diagnostic tool in non-systemic vasculitic neuropathy. Acta Neuropathologica, 2010, 120, 109-116.	7.7	53
135	Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain, 2010, 150, 439-450.	4.2	791
136	Nitric Oxide Synthase Modulates CFA-Induced Thermal Hyperalgesia through Cytokine Regulation in Mice. Molecular Pain, 2010, 6, 1744-8069-6-13.	2.1	71
137	Lack of the serotonin transporter in mice reduces locomotor activity and leads to gender-dependent late onset obesity. International Journal of Obesity, 2010, 34, 701-711.	3.4	37
138	MDL-28170 Has No Analgesic Effect on CCI Induced Neuropathic Pain in Mice. Molecules, 2010, 15, 3038-3047.	3.8	7
139	Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain, 2010, 133, 3166-3180.	7.6	172
140	212 DEFICIENCY OF THE NEGATIVE IMMUNE REGULATOR B7H1 ENHANCES INFLAMMATION AND NEUROPATHIC PAIN AFTER CHRONIC CONSTRICTION INJURY OF MOUSE SCIATIC NERVE. European Journal of Pain Supplements, 2010, 4, 62-62.	0.0	0
141	Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Experimental Neurology, 2010, 222, 153-160.	4.1	26
142	Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology, 2010, 74, 1806-1813.	1.1	158
143	A Key Role for gp130 Expressed on Peripheral Sensory Nerves in Pathological Pain. Journal of Neuroscience, 2009, 29, 13473-13483.	3.6	125
144	Treatment of Fibromyalgia Syndrome With Antidepressants. JAMA - Journal of the American Medical Association, 2009, 301, 198.	7.4	284

#	ARTICLE	IF	CITATIONS
145	Treatment of fibromyalgia syndrome with gabapentin and pregabalin â€“ A meta-analysis of randomized controlled trials. <i>Pain</i> , 2009, 145, 69-81.	4.2	195
146	Mode of action of cytokines on nociceptive neurons. <i>Experimental Brain Research</i> , 2009, 196, 67-78.	1.5	123
147	354 POTENTIAL INVOLVEMENT OF THE TETRODOTOXINâ€NSENSITIVE SODIUM CHANNEL Nav 1.8 IN MUSCLE PAIN. <i>European Journal of Pain</i> , 2009, 13, S107c.	2.8	0
148	Status of immune mediators in painful neuropathies. <i>Current Pain and Headache Reports</i> , 2008, 12, 159-164.	2.9	14
149	A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. <i>Arthritis and Rheumatism</i> , 2008, 59, 1279-1298.	6.7	105
150	Early cytokine gene expression in mouse CNS after peripheral nerve lesion. <i>Neuroscience Letters</i> , 2008, 436, 259-264.	2.1	30
151	Cytokine regulation in animal models of neuropathic pain and in human diseases. <i>Neuroscience Letters</i> , 2008, 437, 194-198.	2.1	80
152	New treatment options for fibromyalgia: critical appraisal of duloxetine. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 525.	2.2	8
153	Cytokine-Induced Pain: Basic Science and Clinical Implications. <i>Reviews in Analgesia</i> , 2007, 9, 87-103.	0.9	14
154	Differential expression patterns of cytokines in complex regional pain syndrome. <i>Pain</i> , 2007, 132, 195-205.	4.2	247
155	Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. <i>Brain, Behavior, and Immunity</i> , 2007, 21, 553-560.	4.1	104
156	Differential expression of cytokines in painful and painless neuropathies. <i>Neurology</i> , 2007, 69, 42-49.	1.1	272
157	Differences in inflammatory pain in nNOSâ€“, iNOSâ€“and eNOSâ€“deficient mice. <i>European Journal of Pain</i> , 2007, 11, 810-818.	2.8	88
158	231 DIFFERENTIAL EXPRESSION PATTERNS OF CYTOKINES IN CRPS I. <i>European Journal of Pain</i> , 2007, 11, S101-S102.	2.8	0
159	Wallerian degeneration and neuropathic pain. <i>Drug Discovery Today Disease Mechanisms</i> , 2006, 3, 351-356.	0.8	16
160	Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. <i>Arthritis and Rheumatism</i> , 2006, 54, 2656-2664.	6.7	214
161	Heterozygous P0 deficiency protects mice from vincristine-induced polyneuropathy. <i>Journal of Neuroscience Research</i> , 2006, 84, 37-46.	2.9	26